Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series.
Authors
Carruthers, Vickyanne
Barnett, Shelby
Rees, Rebecca
Arif, Tasnim
Slater, Olga
Ramanujachar, Ramya
Johnson, Katie
Brown, Sarah
Graham, Catherine
Burke, GA Amos
Publication Date
2022-07Journal Title
Pediatr Blood Cancer
ISSN
1545-5009
Publisher
Wiley
Language
en
Type
Article
This Version
AO
VoR
Metadata
Show full item recordCitation
Carruthers, V., Barnett, S., Rees, R., Arif, T., Slater, O., Ramanujachar, R., Johnson, K., et al. (2022). Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series.. Pediatr Blood Cancer https://doi.org/10.1002/pbc.29722
Abstract
Infantile myofibroma is a rare, benign tumour of infancy typically managed surgically. In a minority of cases, more aggressive disease is seen and chemotherapy with vinblastine and methotrexate may be used, although evidence for this is limited. Chemotherapy dosing in infants is challenging, and vinblastine disposition in infants is unknown. We describe the use of vinblastine therapeutic drug monitoring in four cases of infantile myofibroma. Marked inter- and intrapatient variability was observed, highlighting the poorly understood pharmacokinetics of vinblastine in children, the challenges inherent in treating neonates, and the role of adaptive dosing in optimising drug exposure in challenging situations.
Keywords
ONCOLOGY: BRIEF REPORT, infantile myofibroma, neonate, pharmacokinetics, therapeutic drug monitoring, vinblastine
Identifiers
pbc29722
External DOI: https://doi.org/10.1002/pbc.29722
This record's URL: https://www.repository.cam.ac.uk/handle/1810/336254
Rights
Licence:
http://creativecommons.org/licenses/by/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.